Scarica l'app Stockscreener
32.04
3.26%
-1.08
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decrease in Short Interest - Defense World
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - The AM Reporter
Cantor Fitzgerald Has Weak Forecast for DRUG FY2025 Earnings - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% – Here’s Why - Defense World
Bright Minds Biosciences Independent Director Nils Bottler Sells 100% Of Holding - simplywall.st
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - GlobeNewswire
Bright Minds Biosciences Strengthens Epilepsy Focus with New Advisory Board Members - TipRanks
Can These 5 Epilepsy Experts Accelerate Bright Minds' Breakthrough Drug Development? - StockTitan
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - The Manila Times
Can This CNS Drug Developer's Triple Conference Tour Spark Investor Interest? - StockTitan
How the (DRUG) price action is used to our Advantage - news.stocktradersdaily.com
HC Wainwright Issues Negative Estimate for DRUG Earnings - Defense World
H.C. Wainwright maintains $85 target on Bright Minds stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains $85 target on Bright Minds stock - Investing.com India
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences’ BMB-101: A Promising Contender in Serotonergic Epilepsy Treatment with Strong Market Potential - TipRanks
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS - MarketBeat
Bright Minds Biosciences Dramatic Surge Highlights the High-Stakes Nature of Biotech Investments - HPBL
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - Benzinga
Bright Minds Biosciences Shows Financial Improvement in Latest Report - TipRanks
When (DRUG) Moves Investors should Listen - Stock Traders Daily
SEC Form F-3 filed by Bright Minds Biosciences Inc. - Quantisnow
More Money In The Bank For Bright Minds Biosciences Insiders Who Divested CA$16m - Simply Wall St
How To Buy Bright Minds Biosciences Inc. Stock Online in February 2025 - Traders Union
Long Term Trading Analysis for (DRUG) - Stock Traders Daily
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Cantor Fitzgerald Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Nasdaq
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):